CN113341000A - Method for determining the concentration of Sodium Danshensu and Prunasin in canine plasma - Google Patents
Method for determining the concentration of Sodium Danshensu and Prunasin in canine plasma Download PDFInfo
- Publication number
- CN113341000A CN113341000A CN202011592154.6A CN202011592154A CN113341000A CN 113341000 A CN113341000 A CN 113341000A CN 202011592154 A CN202011592154 A CN 202011592154A CN 113341000 A CN113341000 A CN 113341000A
- Authority
- CN
- China
- Prior art keywords
- solution
- sample
- taking
- prunasin
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/36—Control of physical parameters of the fluid carrier in high pressure liquid systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
- G01N30/724—Nebulising, aerosol formation or ionisation
- G01N30/7266—Nebulising, aerosol formation or ionisation by electric field, e.g. electrospray
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N2030/042—Standards
- G01N2030/045—Standards internal
Landscapes
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Dispersion Chemistry (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
The invention discloses a method for determining the concentration of Sodium Danshensu and Prunasin in canine plasma by an HPLC-MS/MS method.
Description
Technical Field
The invention relates to the field of biological analysis, in particular to a method for determining the concentrations of Sodium Danshessu and Prunasin in canine plasma by an HPLC-MS/MS method.
Background
Hepatic fibrosis is one of the liver diseases. After the human body suffers from hepatic fibrosis, symptoms such as fatigue, weakness, anorexia and the like are easy to appear, and symptoms such as chronic dyspepsia, bleeding and the like are possibly also appeared, and the symptoms can cause great harm to the human body.
The tablet for strengthening body resistance and removing blood stasis is one of the commonly used Chinese patent medicines for treating hepatic fibrosis, and comprises the following main components: schisandrin (Schizandroin), Schisandrin B (gamma-Schisandrin), maosolides (Massonia Lactone), Sodium Danshensu (Sodium Danshensu), Prunasin (Prunasin), Amygdalin (Amygdalin), Naringenin (Naringenin), Quercetin (Quercetin), Rutin (Rutin), phytolaccin (Ombuoside) and its metabolite phytolaccin (Ombuin), Quercitrin (Quercin), Kaempferol (Kaempferol), and Sodium senkyenate (Sodium 5-Hydroxy-2-Decenoic). The toxicity kinetics characteristics of the tablet for strengthening the body resistance and removing blood stasis in the plasma of Beagle dogs (Beagle dogs) are detected, the exposure level of the main components of the medicine in Beagle dogs is evaluated, and the method has important significance for helping to know the action and effect of the medicine in human bodies. Therefore, those skilled in the art are continuously working on the HPLC-MS/MS method for determining the concentration of the main component of the tablet for strengthening body resistance and removing blood stasis in plasma.
Disclosure of Invention
In order to overcome the defects in the prior art, the embodiment of the invention provides a method for determining the concentrations of Sodium Danshensu and Prunasin in canine plasma by an HPLC-MS/MS method, and the working conditions of the HPLC-MS/MS analysis and determination process are as follows:
(1) PHLC conditions:
a chromatographic column: InertStain AQ-C18(2.1 mm. times.50 mm,5.0 μm), SHIMADZU;
column temperature: 35 ℃;
mobile phase A: 0.1% acetic acid-water solution;
mobile phase B: methanol-acetonitrile solution (7/3, v/v);
sample introduction volume: 3.00 mu L;
operating time: 4.80 min;
retention time: sodium Danshensu, about 1.68 min; prunasin, about 1.82 min; osamide, approximately 2.04 min;
(2) and mass spectrum conditions:
mass spectrometry: AB SCIEX API5000 LC/MS/MS system;
an ion source: ESI electrospray ionization;
ionization mode: negative;
vortex ion spray temperature: at 550 ℃.
Further, the method comprises the following steps:
(1) 1.00mg/mL of each of Sodium Danshensu, Prunasin and Osalmide is taken and respectively dissolved in methanol to prepare Sodium Danshensu stock solution, Prunasin stock solution and Osalmide stock solution, and the obtained solution is sealed at the temperature of less than or equal to-15 ℃ and stored in a shading way, wherein Osalmide is taken as an internal standard;
diluting the Sodium Danshensu stock solution and the Prunasin stock solution with methanol solution to a concentration of 2 x 10 respectively5、1.6*105The calibration of ng/mL indicates the sample working solution; mixing the Sodium Danshensu and the Prunasin with equal concentration, and diluting the mixture to 4 x 10 concentration by using methanol solution4、1.6*1041600, 400 and 200ng/mL of calibration marking sample working solution;
diluting the Sodium Danshensu stock solution and the Prunasin stock solution with methanol solution to a concentration of 1.5 x 105、1.0*105ng/mL quality control working solution; mixing the Sodium Danshensu and the Prunasin and diluting to 6 x 10 concentration with methanol solution4600 and 200ng/mL quality control working solution;
diluting the Osalmide stock solution with methanol solution to a concentration of 1 x 10450ng/mL internal standard working solution;
diluting the calibration marker sample working solution to a concentration of 1 x 10 by using a blank matrix48000, 2000, 800, 80, 20, 10ng/mL of the calibration markers, the blank matrix is canine plasma without analyte and internal standard, in this example Sodium Danshensu, Prunasin and osamide;
diluting the quality control working solution with the blank matrix into the quality control samples with the concentrations of 7500, 5000, 300, 30 and 10 ng/mL;
(2) sample treatment: and (3) taking the calibration marker sample and the quality control sample with the same volume, respectively adding 270 mu L of 50ng/mL internal standard working solution, closing a plate, performing vortex mixing, centrifuging, taking 150 mu L of supernatant to the 96-well plate, and adding 100 mu L of methanol solution. Then, the pore plate is sealed, low-speed vortex mixing is carried out, and 3.0 mu L of the mixture is taken to be injected and analyzed on a high performance liquid chromatography mass spectrometer (HPLC-MS/MS);
(3) and (3) preparing a standard curve: making a standard curve by taking Y as aX + b, wherein X is the concentration of the analyte, and Y is the area ratio of chromatographic peaks;
(4) quantitative analysis: and (3) processing the sample to be detected according to the step (2), and calculating the concentrations of Sodium Danshessu and Prunasin in the sample to be detected according to the standard curve obtained in the step (3).
Further, the centrifugation conditions in the step (2) are as follows: centrifuge at 4000rpm for 10min at 10 ℃.
Further, the step (2) further comprises processing a Blank (BK) sample: sucking 30 mu L of blank matrix, adding 270 mu L of methanol solution, sealing the plate, then carrying out vortex mixing, centrifuging at 10 ℃ and 4000rpm for 10min, taking 150 mu L of supernatant after centrifugation, adding 100 mu L of methanol solution, then sealing the plate, carrying out low-speed vortex mixing, and taking 3.0 mu L for analysis.
Further, the step (2) also comprises the processing of a QC0 sample: sucking 30 mu L of blank matrix, adding 270 mu L of the internal standard working solution, sealing the plate, performing vortex mixing, centrifuging at 10 ℃ and 4000rpm for 10min, taking 150 mu L of supernatant into the 96-well plate after centrifugation, adding 100 mu L of methanol solution, sealing the well plate, performing low-speed vortex mixing, and taking 3.0 mu L for analysis.
Further, the step (2) also comprises the processing of the ULOQ without IS sample: adding 270 mu L of methanol solution into a blank substrate without an internal standard at the highest quantitative limit, sealing the plate, then carrying out vortex mixing, centrifuging for 10min at the temperature of 10 ℃ and the speed of 4000rpm, taking 150 mu L of supernatant after centrifugation, putting the supernatant into the 96-well plate, and adding 100 mu L of methanol solution. The well plate was then sealed and mixed by low speed vortexing and 3.0 μ L was taken for analysis.
Further, the step (2) also comprises the treatment of the matrix effect sample: taking 30 mu L blank matrix of a single donor (n is more than or equal to 6), adding 270 mu L methanol solution, carrying out vortex centrifugation, taking 150 mu L supernatant, adding 100 mu L Neat solution, sealing the pore plate, carrying out low-speed vortex mixing, and taking 3.0 mu L for analysis.
Further, the step (2) further comprises the following steps of: taking a blank matrix of a single donor, taking 30 mu L of the blank matrix mixed by a plurality of donors to form the recovery rate sample, adding 270 mu L of methanol solution, carrying out vortex centrifugation, taking 150 mu L of supernatant, adding 100 mu L of liquid, sealing the pore plate, carrying out low-speed vortex mixing, and taking 3.0 mu L for analysis.
The invention has the following beneficial effects: through optimization of technological conditions such as chromatographic columns, solution, mobile phase, retention time and the like, the whole testing process is more feasible, the measurement result is increased accurately, residues are reduced, the accuracy is improved, the recovery rate is high, and the matrix effect and the interference are reduced.
In order to make the aforementioned and other objects, features and advantages of the present invention comprehensible, preferred embodiments accompanied with figures are described in detail below.
Drawings
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
FIG. 1 is a spectrum of a Sodium Danshensu-Reagent sample in an example of the present invention;
FIG. 2 is a spectrum of a Blank sample of Sodium Danshensu-Blank in an example of the present invention;
FIG. 3 is a spectrum of a Sodium Danshensu-QC0 sample according to an example of the present invention;
FIG. 4 is a spectrum of a Sodium Danshensu-Carryover Blank sample in an example of the present invention;
FIG. 5 is a spectrum of a Sodium Danshensu-LLOQ sample in an example of the present invention;
FIG. 6 is a spectrum of a Sodium Danshensu-ULOQ sample in an example of the present invention;
FIG. 7 is a spectrum of a Prunasin-Reagent blank sample in an example of the present invention;
FIG. 8 is a spectrum of a Prunasin-Blank sample in an example of the present invention;
FIG. 9 is a spectrum of a sample of Prunasin-QC0 in an example of the present invention;
FIG. 10 is a spectrum of a sample of Prunasin-Carryover Blank in an example of the present invention;
FIG. 11 is a spectrum of a sample of Prunasin-LLOQ in an example of the present invention;
FIG. 12 is a spectrum of a sample of Prunasin-ULOQ in an example of the present invention;
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
In the description of the present invention, it should be noted that the terms "upper", "lower", "bottom", "inner", "outer", and the like indicate orientations or positional relationships based on those shown in the drawings, and are only for convenience of description and simplicity of description, but do not indicate or imply that the referred device or element must have a specific orientation, be constructed in a specific orientation, and be operated, and thus, should not be construed as limiting the present invention. Furthermore, the terms "first", "second", etc. are used for descriptive purposes only and are not to be construed as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Thus, a feature defined as "first," "second," etc. may explicitly or implicitly include one or more of that feature.
In order to achieve the above objects, the present invention provides a method for determining the concentrations of Sodium Danshessu and Prunasin in canine plasma by HPLC-MS/MS method, comprising the following steps.
Working conditions of HPLC-MS/MS analysis and determination process
(1) And HPLC conditions are as follows:
a chromatographic column: InertStain AQ-C18(2.1 mm. times.50 mm,5.0 μm), SHIMADZU;
column temperature: 35 ℃;
mobile phase A: 0.1% acetic acid-water solution;
mobile phase B: methanol-acetonitrile solution (7/3, v/v);
pump gradient:
sample introduction volume: 3.00 mu L;
operating time: 4.80 min;
retention time: sodium Danshensu, about 1.68 min; prunasin, about 1.82 min; osamide, approximately 2.04 min;
(2) and mass spectrum conditions:
mass spectrometry: AB SCIEX API5000 LC/MS/MS system;
an ion source: ESI electrospray ionization;
ionization mode: negative;
vortex ion spray temperature: 550 ℃;
second, sample configuration
Preparation of stock solution: 1.00mg/mL of each of Sodium Danshensu, Prunasin and Osalmide is taken and respectively dissolved in methanol to prepare Sodium Danshensu stock solution, Prunasin stock solution and Osalmide stock solution, and the obtained solution is sealed at the temperature of less than or equal to-15 ℃ and stored in a shading way, wherein Osalmide is taken as an internal standard; as shown in table 1.
Preparation of calibration marking sample working solution: diluting the Sodium Danshensu stock solution and the Prunasin stock solution with methanol solution to a concentration of 2 x 10 respectively5、1.6*105The calibration of ng/mL indicates the sample working solution; mixing the Sodium Danshensu and the Prunasin with equal concentration, and diluting the mixture to 4 x 10 concentration by using methanol solution4、1.6*1041600, 400 and 200ng/mL of calibration marking sample working solution; as shown in table 2.
Preparing a quality control working solution: diluting the Sodium Danshensu stock solution and the Prunasin stock solution with methanol solution to a concentration of 1.5 x 105、1.0*105ng/mL quality control working solution; mixing the Sodium Danshensu and the Prunasin and diluting to 6 x 10 concentration with methanol solution4600 and 200ng/mL quality control working solution; as shown in table 3.
Preparing an internal standard working solution: diluting the Osalmide stock solution with methanol solution to a concentration of 1 x 10450ng/mL internal standard working solution; as shown in table 4.
Preparation of neat solution: diluting the quality control solution and the internal standard working solution into a neat solution by using a methanol solution; as shown in table 5.
Note: the calibration marking sample working solution, the quality control working solution, the internal standard working solution and the pure solution with the recovery rate and the matrix effect can be changed in the dilution process/volume as long as the final concentration is unchanged. As long as the solution ID is unique, the solution ID can be changed without affecting the traceability of the experiment. And were all prepared at room temperature.
Calibration of the arrangement of the markers: diluting the calibration marker sample working solution to a concentration of 1 x 10 by using a blank matrix48000, 2000, 800, 80, 20, 10ng/mL of the calibrator, the blank matrix being canine plasma without analyte and internal standard, in this example Sodium Danshessu, Prunnasin and Osalmide; as shown in table 6.
Preparation of quality control samples: diluting the quality control working solution with the blank matrix into the quality control samples with the concentrations of 7500, 5000, 300, 30 and 10 ng/mL; as shown in table 7.
Third, sample treatment
And (3) taking a 96-well plate, and labeling a calibration marker sample, a quality control sample, a blank sample, a QC0 sample, a ULOQ without IS sample, a Reagent sample, a matrix effect sample and a recovery rate sample on the 96-well plate to form a sample map.
Sucking 30 mu L of the calibration marker sample and the quality control sample and respectively placing the calibration marker sample and the quality control sample into a calibration marker sample hole and a quality control sample hole;
sucking 30 mu L of blank matrix into a blank sample hole, wherein the blank sample has no analyte and no internal standard;
sucking 30 μ L of blank matrix and placing into QC0 sample well;
sucking 30 μ L of blank matrix without internal standard at the highest limit of quantitation and placing the blank matrix into the ULOQ without IS sample hole;
pipette 30.0 μ L of aqueous solution into the wells of the Reagent sample in the 96-well plate.
Sucking 30 mu L blank matrix of a single donor (n is more than or equal to 6) and putting the blank matrix into a matrix effect sample hole;
a single donor blank was removed and 30. mu.L of the pooled blank from multiple donors was pipetted into the recovery sample well.
And adding 270 mu L of the internal standard working solution into the calibration marker sample, the quality control sample and the QC0 sample respectively, sealing plates, then, uniformly mixing by vortex, and centrifuging for 10min at the conditions of 10 ℃ and 4000 rpm. After centrifugation, 150. mu.L of the supernatant was transferred to the 96-well plate, and 100. mu.L of methanol solution was added. The well plate was then sealed and mixed by low speed vortexing and 3.0 μ L was taken for analysis.
Adding 270 mu L of methanol solution into the blank sample, the ULOQ without IS sample and the Reagent sample, sealing the plates, vortexing and mixing uniformly, and centrifuging for 10min at 10 ℃ and 4000 rpm. After centrifugation, 150. mu.L of the supernatant was transferred to the 96-well plate, and 100. mu.L of methanol solution was added. The well plate was then sealed and mixed by low speed vortexing and 3.0 μ L was taken for analysis.
Adding 270 mu L of methanol solution into the matrix effect sample and the recovery rate sample, sealing a plate, then whirling and mixing uniformly, and centrifuging for 10min at 10 ℃ and 4000 rpm. After centrifugation, 150. mu.L of the supernatant was applied to the 96-well plate, and 100. mu.L of the Neat solution was added. The well plate was then sealed and mixed by low speed vortexing and 3.0 μ L was taken for analysis.
Fourth, establishment of linear regression model
And detecting the calibration marker sample and the quality control sample according to the chromatographic and mass spectrum conditions, and processing chromatogram acquisition and chromatographic peak integration by software analysis 1.6.3 and Applied Biosystem. The chromatographic peak area ratio of the Sodium Danshensu internal standard Osalmide and the Prunasin internal standard Osalmide is taken as the ordinate, the concentration of Sodium Danshensu and Prunasin in the canine plasma is taken as the abscissa, and the weight is used for weighting (the weight is 1/X)2) The least square method is used for carrying out linear regression by using the concentration (X) of Sodium Danshensu and Prunasin in canine plasma and the area ratio (Y) of chromatographic peaks, and the constructed linear regression equation (Y ═ aX + b) is a standard curve. The results show that the calibration curves of Sodium Danshensu and Prunasin range from 10.0ng/mL to 10000 ng/mL, and the standard curves are made well linearly.
Fifth, quantitative analysis
And (3) treating the test sample according to the method of the sample treatment step, and calculating according to the standard curve equation obtained in the sample treatment step to obtain the concentrations of the analytes Sodium Danshessu and Prunasin in the sample to be detected.
Sixth, evaluation of test methods
The Blank (BK) sample, QC0 sample, and ULOQ with IS sample were used to correct each other to reduce interference.
The matrix effect sample and the recovery sample are used to evaluate the matrix effect and the recovery of the method. The analysis shows that the matrix effect of the method is 100-110%. The analytical SodiumDanshensu recovery rate of the process was: 72.5% -100%, and the recovery rate of Prunasin is as follows: 90 to 100 percent.
The principle and the implementation mode of the invention are explained by applying specific embodiments in the invention, and the description of the embodiments is only used for helping to understand the method and the core idea of the invention; meanwhile, for a person skilled in the art, according to the idea of the present invention, there may be variations in the specific embodiments and the application scope, and in summary, the content of the present specification should not be construed as a limitation to the present invention.
Claims (8)
1. A method for measuring the concentration of Sodium Danshensu and Prunasin in canine plasma by HPLC-MS/MS method is characterized in that,
working conditions of PHLC-MS/MS analysis determination process
(1) PHLC conditions:
a chromatographic column: InertStain AQ-C18(2.1mmx50mm,5.0 μm), SHIMADZU;
column temperature: 35 ℃;
mobile phase A: 0.1% acetic acid-water solution;
mobile phase B: methanol-acetonitrile solution (7/3, v/v);
sample introduction volume: 3.00 mu L;
operating time: 4.80 min;
retention time: sodium Danshensu, about 1.68 min; prunasin, about 1.82 min; osamide, approximately 2.04 min;
(2) and mass spectrum conditions:
mass spectrometry: AB SCIEX API5000 LC/MS/MS system;
an ion source: ESI electrospray ionization;
ionization mode: negative;
vortex ion spray temperature: at 550 ℃.
2. The method of claim 1, comprising the steps of:
(1) 1.00mg/mL of each of Sodium Danshensu, Prunasin and Osalmide is taken and respectively dissolved in methanol to prepare Sodium Danshensu stock solution, Prunasin stock solution and Osalmide stock solution, and the obtained solution is sealed at the temperature of less than or equal to-15 ℃ and stored in a shading way, wherein Osalmide is taken as an internal standard;
diluting the Sodium Danshensu stock solution and the Prunasin stock solution with methanol solution to a concentration of 2 x 10 respectively5、1.6*105The calibration of ng/mL indicates the sample working solution; mixing the Sodium Danshensu and the Prunasin with equal concentration, and diluting the mixture to 4 x 10 concentration by using methanol solution4、1.6*1041600, 400 and 200ng/mL of calibration marking sample working solution;
diluting the Sodium Danshensu stock solution and the Prunasin stock solution with methanol solution to a concentration of 1.5 x 105、1.0*105ng/mL quality control working solution; mixing the Sodium Danshensu and the Prunasin and diluting to 6 x 10 concentration with methanol solution4600 and 200ng/mL quality control working solution;
diluting the Osalmide stock solution with methanol solution to a concentration of 1 x 10450ng/mL internal standard working solution;
diluting the calibration marker sample working solution to a concentration of 1 x 10 by using a blank matrix48000, 2000, 800, 80, 20, 10ng/mL of the calibrator, the blank matrix being canine plasma without analyte and internal standard, in this example Sodium Danshessu, Prunnasin and Osalmide;
diluting the quality control working solution with the blank matrix into the quality control samples with the concentrations of 7500, 5000, 300, 30 and 10 ng/mL;
(2) sample treatment: and (3) taking the calibration marker sample and the quality control sample with the same volume, respectively adding 270 mu L of 50ng/mL internal standard working solution, closing a plate, performing vortex mixing, centrifuging, taking 150 mu L of supernatant to the 96-well plate, and adding 100 mu L of methanol solution. Then, the pore plate is sealed, low-speed vortex mixing is carried out, and 3.0 mu L of the mixture is taken to be injected and analyzed on a high performance liquid mass spectrometer (HPLC-MS/MS);
(3) and (3) preparing a standard curve: making a standard curve by taking Y as aX + b, wherein X is the concentration of the analyte, and Y is the area ratio of chromatographic peaks;
(4) quantitative analysis: and (3) processing the sample to be detected according to the step (2), and calculating the concentrations of Sodium Danshessu and Prunasin in the sample to be detected according to the standard curve obtained in the step (3).
3. The method according to claim 2, wherein the centrifugation conditions in step (2) are: centrifuge at 4000rpm for 10min at 10 ℃.
4. The method of claim 3, wherein step (2) further comprises processing a Blank (BK) sample by: sucking 30 mu L of blank matrix, adding 270 mu L of methanol solution, sealing the plate, then carrying out vortex mixing, centrifuging at 10 ℃ and 4000rpm for 10min, taking 150 mu L of supernatant after centrifugation, adding 100 mu L of methanol solution, then sealing the plate, carrying out low-speed vortex mixing, and taking 3.0 mu L for analysis.
5. The method according to claim 4, wherein the step (2) further comprises the processing of QC0 samples: sucking 30 mu L of blank matrix, adding 270 mu L of the internal standard working solution, sealing the plate, performing vortex mixing, centrifuging at 10 ℃ and 4000rpm for 10min, taking 150 mu L of supernatant into the 96-well plate after centrifugation, adding 100 mu L of methanol solution, sealing the well plate, performing low-speed vortex mixing, and taking 3.0 mu L for analysis.
6. The method according to claim 5, wherein the step (2) further comprises processing the ULOQ without IS sample: adding 270 mu L of methanol solution into a blank substrate without an internal standard at the highest quantitative limit, sealing the plate, then carrying out vortex mixing, centrifuging for 10min at the temperature of 10 ℃ and the speed of 4000rpm, taking 150 mu L of supernatant after centrifugation, putting the supernatant into the 96-well plate, and adding 100 mu L of methanol solution. The well plate was then sealed and mixed by low speed vortexing and 3.0 μ L was taken for analysis.
7. The method according to claim 6, wherein the step (2) further comprises processing the matrix effect sample: taking 30 mu L blank matrix of a single donor (n is more than or equal to 6), adding 270 mu L methanol solution, carrying out vortex centrifugation, taking 150 mu L supernatant, adding 100 mu L Neat solution, sealing the pore plate, carrying out low-speed vortex mixing, and taking 3.0 mu L for analysis.
8. The method of claim 7, wherein the step (2) further comprises processing the recovery sample: taking a blank matrix of a single donor, taking 30 mu L of the blank matrix of a mixture of a plurality of donors to form the recovery rate sample, adding 270 mu L of methanol solution, performing vortex centrifugation, taking 150 mu L of supernatant, adding 100 mu L of Neat solution, sealing a pore plate, performing low-speed vortex mixing, and taking 3.0 mu L for analysis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019114215463 | 2019-12-31 | ||
| CN201911421546.3A CN111198234A (en) | 2019-12-31 | 2019-12-31 | Method for determining the concentration of Sodium Danshensu and Prunasin in canine plasma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113341000A true CN113341000A (en) | 2021-09-03 |
| CN113341000B CN113341000B (en) | 2023-02-10 |
Family
ID=70744429
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911421546.3A Withdrawn CN111198234A (en) | 2019-12-31 | 2019-12-31 | Method for determining the concentration of Sodium Danshensu and Prunasin in canine plasma |
| CN202011592154.6A Active CN113341000B (en) | 2019-12-31 | 2020-12-29 | Method for determining concentration of sodium danshensu and prunasin in dog plasma |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911421546.3A Withdrawn CN111198234A (en) | 2019-12-31 | 2019-12-31 | Method for determining the concentration of Sodium Danshensu and Prunasin in canine plasma |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN111198234A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005270059A1 (en) * | 2004-07-02 | 2006-02-09 | E.I. Du Pont De Nemuors And Company | Antifungal polypeptides |
| CN101816715A (en) * | 2009-11-24 | 2010-09-01 | 云南理想药业有限公司 | Method for measuring content of Danshensu in shenshuaining capsules by utilizing HPLC method |
| CN110078778A (en) * | 2019-05-15 | 2019-08-02 | 广西壮族自治区中国科学院广西植物研究所 | A method of removing prunasin from passion fruit pericarp crude extract |
-
2019
- 2019-12-31 CN CN201911421546.3A patent/CN111198234A/en not_active Withdrawn
-
2020
- 2020-12-29 CN CN202011592154.6A patent/CN113341000B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005270059A1 (en) * | 2004-07-02 | 2006-02-09 | E.I. Du Pont De Nemuors And Company | Antifungal polypeptides |
| CN101816715A (en) * | 2009-11-24 | 2010-09-01 | 云南理想药业有限公司 | Method for measuring content of Danshensu in shenshuaining capsules by utilizing HPLC method |
| CN110078778A (en) * | 2019-05-15 | 2019-08-02 | 广西壮族自治区中国科学院广西植物研究所 | A method of removing prunasin from passion fruit pericarp crude extract |
Non-Patent Citations (6)
| Title |
|---|
| JIANG JJ 等: "High-throughput determination of sodium danshensu in beagle dogs by the lc-ms/msmethod，employing liquid-liquid extraction based on 96-well format plates", 《MOLECULES》 * |
| WU SY 等: "Simultaneous determination of the potent anti-tuberculosis regimen—Pyrazinamide, ethambutol, protionamide, clofazimine in beagle dog plasma using LC–MS/MS method coupled with 96-well format plate", 《JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS》 * |
| 刘姗 等: "UPLC-MS/MS法同时测定扶正化瘀胶囊中12种成分", 《中草药》 * |
| 智红英 等: "高效液相色谱法测定犬血浆中丹参素钠", 《中草药》 * |
| 王淑萍: "济泰片药效物质基础及药代动力学研究", 《中国博士学位论文全文数据库 医药卫生科技辑》 * |
| 郭咪咪 等: "HPLC测定长柄扁桃仁及饼粕中苦杏仁苷与野黑樱苷", 《现代食品科技》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113341000B (en) | 2023-02-10 |
| CN111198234A (en) | 2020-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stokes et al. | Development of a liquid chromatography–mass spectrometry method for the high-accuracy determination of creatinine in serum | |
| CN111157641B (en) | Method for determining content of carbamazepine in human plasma by HPLC-MS-MS method | |
| WO2022067533A1 (en) | Method for simultaneously testing phylloquinone and menaquinone-4 in trace blood | |
| Rúbies et al. | Determination of avermectins: a QuEChERS approach to the analysis of food samples | |
| Maršálek et al. | Simultaneous determination of ten anticoagulant rodenticides in tissues by column-switching UHPLC-ESI-MS/MS | |
| Wang et al. | Application of air-assisted liquid-liquid microextraction for determination of some fluoroquinolones in milk powder and egg samples: Comparison with conventional dispersive liquid-liquid microextraction | |
| CN113219074A (en) | Method for measuring concentration of Rutin and Ombuoside in dog plasma by HPLC-MS/MS method | |
| Young et al. | A rapid SPE-based analytical method for UPLC/MS/MS determination of aminoglycoside antibiotic residues in bovine milk, muscle, and kidney | |
| Ahrens et al. | Detection of stimulants and narcotics by liquid chromatography-tandem mass spectrometry and gas chromatography-mass spectrometry for sports doping control | |
| CN113189210B (en) | HPLC-MS/MS method for measuring concentration of amygdalin, naringenin and quercetin in blood plasma | |
| CN113341000B (en) | Method for determining concentration of sodium danshensu and prunasin in dog plasma | |
| CN113252804B (en) | Method for measuring concentration of maxolide, schizandrol A and schizandrin B in plasma and internal standard working solution thereof | |
| Woźniakiewicz et al. | Development of the MAE/UHPLC-MS-TOF method for determination of benzodiazepines in human bio-fluids for toxicological analysis | |
| González-Rubio et al. | Supramolecular solvents for making comprehensive liquid-liquid microextraction in multiclass screening methods for drugs of abuse in urine based on liquid chromatography-high resolution mass spectrometry | |
| CN102565252B (en) | Method for detecting content of homocysteine in blood or urine | |
| CN111157639A (en) | Method for determining concentration of ibuprofen in rat plasma by high performance liquid mass spectrometry | |
| Bogusz et al. | Impact of biological matrix, drug concentration, and method of isolation on detectability and variability of retention index values in gas chromatography | |
| CN108387656B (en) | Method for detecting bis (hydroxymethyl) imidazolidinyl urea in cosmetics through liquid chromatography-mass spectrometry | |
| Namera et al. | Monolithic spin column: a new extraction device for analysis of drugs in urine and serum by GC/MS and HPLC/MS | |
| Zhou et al. | Development and validation of LC–MS method for the determination of hydroxyzine hydrochloride in human plasma and subsequent application in a bioequivalence study | |
| CN113567590B (en) | Method for determining imiquimod component content in SD rat plasma by HPLC-MS-MS method | |
| CN105699575A (en) | Method and kit for testing cortisol in saliva by efficient liquid chromatogram and tandem mass spectrometry combination technology | |
| Wu et al. | Simultaneous determination of 17 toxic alkaloids in human fluids by liquid chromatography coupled with electrospray ionization tandem mass spectrometry | |
| CN111879875A (en) | Method for determining cytarabine and uridine arabinoside in blood plasma | |
| He et al. | Determination of macrocyclic lactone drug residues in animal muscle by liquid chromatography/tandem mass spectrometry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |